Advanced urothelial carcinoma, Sarcopenia Advanced urothelial carcinoma, Sarcopenia
Conditions
Interventions
Priscribe Ninjin'yoeito 5-7.5 g/day orally for patients with advanced urothelial carcinoma who recieve platinum-based chemotherapy during 2 months
Sponsors
Okamoto Teppei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with advanced urothelial carcinoma who recieve platinum-based chemotherapy (Age; 65-90 years) 2. Patients who understand and are willing to participate this study. 3. Patients without a severe general condition due to progressive disease. 4. Patients without an abnormality in liver function and serum potassium level. 5. Patients who do not take other harbal medicines which have supportive roles for cancer treatment.
Exclusion criteria
Exclusion criteria: 1. Patients can not take a harbal medicine due to dysphagia and/or tube feeding. 2. Patients who have already took other harbal medicines which have supportive roles for cancer treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the change rates of psoas muscle area of study participants with those of historical cohort 8 weeks after the study commencement | — |
Secondary
| Measure | Time frame |
|---|---|
| The evaluation of change in frailty, body composition, and serum grelin levels 4 and 8 weeks after the study. | — |
Contacts
Public ContactTeppei Okamoto
Hirosaki University Hospital
Outcome results
None listed